Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A "Risk Factors" in Schering-Plough's 2008 10-K, filed Feb. 27, 2009.

Endnotes

1. SVR, the protocol specified primary efficacy endpoint, is defined as achievement of undetectable HCV-RNA at 24 weeks after the end of treatment. Per protocol, if a patient does not have a 24-week post-treatment assessment, the patient's 12-week post-treatment assessment will be utilized.

2. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 Final Results: SVR 24 from a Phase 2 study of Boceprevir Plus PegIntron (Peginterferon alfa-2b)/Ribavirin in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C. 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting; April 22-26, Copenhagen, Denmark; oral presentation, Abstract No. 4.

3. Intention-To-Treat (ITT) analysis - includes any patient who has taken at least one dose of any study drug.

4. Sulkowski M, Shiffman M, Afdhal N, et al. Hemoglobin decline is associated with SVR among HCV genotype 1 infected persons treated with peginterferon (PEG)/ribavirin (RBV): Analysis from the IDEAL Study. 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting; April 22-26, Copenhagen, Denmark; oral presentation, Abstract No. 126.

5. Reesink HW, Bergmann JF, de Bruijne J, et al. Safety and Antiviral Activity of SCH 900518 Administered as Monotherapy and in Combination with Peginterferon Alfa-2b to Naive and Treatment-Experienced HCV Infected Patients. 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting; April 22-26, Copenhagen, Denmark; oral presentation, Abstract No. 86.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- RealMed has been ranked the #1 ... 2009 Top 20 Best in KLAS Awards: ... is a dynamic revenue cycle management solution ... healthcare providers and all payers. ... in vendor performance measurement in the software, ...
(Date:12/16/2009)... Greenway Medical Technologies, Inc. today announced that its ... management and interoperability solution, Prime Suite® 2011, ... annual 2009 Top 20 Best in KLAS ... ,, For practices having between six and 25 ... in KLAS in ambulatory EMR for the fourth ...
(Date:12/16/2009)... N.J. and ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ ... ) and NanoBio Corporation today announced an exclusive ... for the over-the-counter (OTC) use of NB-001, a ... the treatment of cold sores. Developed by NanoBio, ... that causes cold sores, herpes labialis . ...
Breaking Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2Booshoot Founder 26amp 3B CEO Jackie Heinricher Honored as Visionary Entrepreneur by Martha Stewart 14412 1Booshoot Founder 26amp 3B CEO Jackie Heinricher Honored as Visionary Entrepreneur by Martha Stewart 14412 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 14410 1Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 14410 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 14410 3Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 1Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 2Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 3
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
... Calif., March 19 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... a letter from the FDA that outlines what the ... resume clinical studies of Oxycyte(R) in TBI. Oxycyte is ... in response to the company,s request for formal dispute ...
Other Medicine Technology:Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 2Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 3
(Date:12/16/2009)... Ensure and Encourage Access to Quality, Cost-Effective Care , ... ... of Congress have debated the best ways to rein in runaway ... reform. An important part of the ongoing discussion includes how ... care providers besides doctors of medicine (MDs) or osteopathy (DOs). ...
(Date:12/16/2009)... leader of Digital Pen and Paper technology and the provider ... today announced that it is ranked among the Fastest Growing ... 2009. , ... (PRWEB) December 16, ... for the capture, digitalization and management of handwritten data. Kayentis ...
(Date:12/16/2009)... expert says, , , WEDNESDAY, Dec. 16 (HealthDay News) -- ... to die when they receive an implantable cardioverter defibrillator, ... people, ages 65 to 85, who were eligible for ... measure of the heart,s pumping ability) of 35 percent ... were treated with standard medication and an implanted defibrillator ...
(Date:12/16/2009)... Shoppers like knowing if their salad ... But grocers have found it burdensome to implement ... requiring them to provide the information at point ... easyCOOLnow.com for easily making grocery and produce ... that require retailers of unprocessed fruits, vegetables and ...
(Date:12/16/2009)... A new software program developed by CareRise ... facilities to calculate their staffing needs as it relates ... allows inpatient healthcare facilities to calculate their mandatory nurse-to-patient ... and receive a daily report as to how it ... leader in risk management in the healthcare industry, has ...
Breaking Medicine News(10 mins):Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News:Implanted Defibrillator Might Extend Life 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2
... An outbreak of hand, foot-and-mouth disease in eastern Sarawak state ... are saying that they would shut down all schools in ... country. // ,The virus, which causes the disease, ... four have even succumbed to it. "In peninsular Malaysia, the ...
... has receded and with no new case cropped up in ... serve chicken dishes on board.// ,The usual favourites ... toast were sighted on many flights Wednesday morning. ... back on the list," said Sunil Taneja, director business development, ...
... advancements have had the potential to revolutionize diverse areas// ... The Internet has indeed made the world a smaller ... has been a parallel increase in the incidence of ... of late become a playground that allows people to ...
... to Multidrug Resistant Staphylococcus aureus (MRSA) in the northwest has ... undergo a surgery due to this infection. On such ... refuses to be operated due to the fear of acquiring ... Yorks, to be treated privately because of the high risk ...
... A new study has now raised the possibility of ... increased risk of breast cancer//. Salts of metals like ... on breast cancer cells, leading to malignant transformation. ... found to accelerate the growth of breast cancer cell ...
... children in Ecuador whose mothers were exposed to pesticides while ... copy geometric figures as compared to a control group. This ... issue of Paediatrics. ,Philippe Grandjean, ... led a team of researchers and analyzed data on 72 ...
Other Medicine News:Health News:Cyber Sex, No Longer A Fantasy Of The Mind 2Health News:Aluminum Salts In Underarm Deodorants Increase Risk Of Breast Cancer 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: